In very close proximity to the Swiss Federal Institute of Technology (ETH), the University and Zurich University Hospital, a science park for life science companies and institutions has developed in the last two decades, which has now acquired both national and international significance. On a base area of 55,000 m2, the park now hosts 55 companies and many academic institutions representing a healthy mix of young start-ups and global companies as well as university clinics, institutes, and research groups.
In the Bio-Technopark, it is possible to rent ultramodern laboratories, offices, and complex infrastructure for research and development purposes. The premises offered include fully-equipped laboratory facilities with communal infrastructure, and individual rental areas in different sizes and locations and with different fit-out standards. The Bio-Technopark is still being developed and gradually fitted out.
The Bio-Technopark promotes the transfer of knowledge and technology, as well as the foundation and building up of life science companies. In addition to advice, coaching, and support for those who are setting up and developing companies and looking for financing, its services include the organization of events that focus on networking, facilitating the exchange of ideas between specialists, and advanced training.
Proteomedix and New Horizon Health Limited enter into a research and development partnership
Schlieren-Zurich, Switzerland, September 21, 2021. Proteomedix, the Swiss cancer diagnostics company has entered into a research and development partnership with New Horizon Health Limited (6606.SEHK). To support the joint program New Horizon Health has invested CHF 3.0 million in a convertible loan in Proteomedix. The partnership builds on complimentary platform...
Anjarium Biosciences Raises CHF 55.5M ($61M) Series A Financing to Develop Next-Generation Non-viral Gene Therapies
SCHLIEREN, ZURICH, September 16, 2021 — Anjarium Biosciences AG (“Anjarium”), a biotech company focused on creating and delivering a new class of non-viral gene therapies today announced the closing of a CHF55.5M ($61M) Series A financing. The round was co-led by Abingworth and Gimv, with significant participation from Omega Funds,...